Discount banner b26cfd0bc994d525c830a167ad93d0c19724a63776637770540876f8c5116b58
Hypersensitivity Pneumonitis Market Research Report – Global Forecast till 2023

Hypersensitivity Pneumonitis Market Research Report – Global Forecast till 2023

ID: MRFR/HC/3228-HCRR | May, 2018 | Region: Global | 110 pages | Half-Cooked Research Reports

Hypersensitivity Pneumonitis Market Research Report, By Type (Acute, Subacute, Chronic), By Therapy (Diagnosis (Chest Lung Function Tests, X-Ray, Lung Biopsy) Treatment (Pharmacological (Corticosteroid))), End User (Hospital) - Global Forecast till 2023 



Market Scenario:

Hypersensitivity pneumonitis is a complex syndrome caused due to exposure to a variety of organic particles. Hypersensitivity pneumonitis is divided into three types, acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis which is based on the based on the duration of the illness. According to the American Academy of Allergy, Asthma & Immunology (2013), 10%-30% of the global population suffers from allergic rhinitis. Increasing prevalence of patients suffering from hypersensitivity pneumonitis, and increasing pollution have boosted the growth of the market. Additionally, According to the American Academy of Allergy, Asthma & Immunology, in 2013, globally, sensitization rates to one or more common allergens among school children is approximately 40%-50% and in 2012, 10.6% children were diagnosed with respiratory allergies. Moreover, increasing prevalence of respiratory diseases, increasing healthcare expenditure, and strong government support for research & development have also contributed to the growth of the market. Rising geriatric population also supports the growth of the market. However, lack of long term treatment and awareness about the diseases may lead to slow the growth of the market.


The global hypersensitivity pneumonitis market is expected to grow at a CAGR of 8.4% during forecast period. 



Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Medical Devices Companies

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories 



Figure 1:- Global Hypersensitivity pneumonitis market share,
by region

Hypersensitivity Pneumonitis Market


Sources: WHO, annual reports, press release, white paper, and company presentation 



Segmentation


The global hypersensitivity pneumonitis market is segmented on the basis of types, therapy, and end users.


On the basis of types, the market is segmented into acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis.


On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest lung function tests, X-ray, lung biopsy, and others. Treatment is further classified into pharmacological and non-pharmacological. Pharmacological is further segmented into corticosteroid therapy, immunosuppressive therapy and others.


On the basis of end users, the market is segmented into hospital, clinics, and others. 


 


Regional Analysis


America commands the largest share in the global hypersensitivity pneumonitis market owing to a relatively larger patient population suffering from respiratory allergy and huge geriatric population. According to the Asthma and Allergy Foundation of America, in 2015, 8.2% of adults and 8.4% of children were diagnosed with hay fever. The report also states that, annual cost of allergies exceeds USD 18 billion and food allergies cost about USD 25 billion per year. Changing lifestyle, high healthcare spending and increasing geriatric population have boosted the growth of the market in America. Additionally, increasing awareness among the people regarding different diagnostic procedures has also supported the growth of the market.


Europe is the second largest market for hypersensitivity pneumonitis, which is followed by Asia Pacific. Availability of funds for research, changing environment conditions and government support for research & development will drive the market.


Asia Pacific is expecting fastest growth for the market due to the presence of a huge patient population, presence of huge opportunity in the market, and huge geriatric population. India and China are the major contributors for the market. According to the WHO in 2013, approximately 20-30% of Indian population suffers from at least one allergic disease and 8.7% of the total china’s population suffers from allergic rhinitis. Increasing prevalence of diseases have boosted the growth of the Asia Pacific market.


On the other hand, the Middle East & Africa holds the least share in the global hypersensitivity pneumonitis market due limited development in the healthcare sector and poor economy in Africa region. Majority of the market of this region is held by the Middle East due to huge healthcare spending.


 


Research Methodology

Hypersensitivity Pneumonitis Market-


Sources: WHO, annual reports, press release, white paper, and company presentation


 


Key players for global hypersensitivity pneumonitis market


The key players for the global hypersensitivity pneumonitis market: Novartis (Switzerland), Abbott (U.S.), AstraZeneca (U.K), Abbott (US) Eli Lilly (U.S.), Bayer Cropscience Ltd. (U.S.).,  Sunpharma (India), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), Sanofi (France), and Novo Nordisk (Denmark).

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Hypersensitivity Pneumonitis Market, by Type

6.1 Introduction

6.2 Acute Hypersensitivity Pneumonitis

Market Estimates & Forecast, 2017 – 2023

6.3 Sub-acute Hypersensitivity Pneumonitis

Market Estimates & Forecast, 2017 – 2023

6.4 Chronic Hypersensitivity Pneumonitis

Market Estimates & Forecast, 2017 – 2023

Chapter 7. Global Hypersensitivity Pneumonitis Market, by Therapy

7.1 Introduction

7.2 Diagnosis

Market Estimates & Forecast, 2017 – 2023

7.2.1 Chest Lung Function Tests

7.2.2 X-ray

7.2.3 Lung Biopsy

7.2.4 Others

7.3 Treatment

Market Estimates & Forecast, 2017 – 2023

7.3.1 Pharmacological

7.3.1.1 Corticosteroid Therapy

7.3.1.2 Immunosuppressive Therapy

7.3.1.3 Others

7.3.2 Non-Pharmacological

Chapter 8 Global Hypersensitivity Pneumonitis Market, by End User

8.1 Introduction

8.2 Hospitals

8.2.1 Market Estimates & Forecast, 2017 – 2023

8.3 Clinics

8.2.2 Market Estimates & Forecast, 2017 – 2023

8.4 Others

Chapter 9. Global Hypersensitivity Pneumonitis Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K.

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Novartis AG

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Abbott

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Eli Lilly

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Sunpharma

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Sanofi

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Novo Nordisk

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 AstraZeneca

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical industry

Chapter 13 Appendix



LIST OF TABLES

Table 1 Hypersensitivity Pneumonitis Industry Synopsis, 2017 – 2023

Table 2 Global Hypersensitivity Pneumonitis Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Global Hypersensitivity Pneumonitis Market by Region, 2017 – 2023, (USD Million)

Table 4 Global Hypersensitivity Pneumonitis Market by Types, 2017 – 2023, (USD Million)

Table 5 Global Hypersensitivity Pneumonitis Market by Therapy, 2017 – 2023, (USD Million)

Table 6 Global Hypersensitivity Pneumonitis Market by End Users, 2017 – 2023, (USD Million)

Table 7 North America Hypersensitivity Pneumonitis Market by Types, 2017 – 2023, (USD Million)

Table 8 North America Hypersensitivity Pneumonitis Market by Therapy, 2017 – 2023, (USD Million)

Table 9 North America Hypersensitivity Pneumonitis Market by End Users, 2017 – 2023, (USD Million)

Table 10 US Market by Types, 2017 – 2023, (USD Million)

Table 11 US Hypersensitivity Pneumonitis Market by Therapy, 2017 – 2023, (USD Million)

Table 12 US Hypersensitivity Pneumonitis Market by End Users, 2017 – 2023, (USD Million)

Table 13 Canada Market by Types, 2017 – 2023, (USD Million)

Table 14 Canada Hypersensitivity Pneumonitis Market by Therapy, 2017 – 2023, (USD Million)

Table 15 Canada Hypersensitivity Pneumonitis Market by End Users, 2017 – 2023, (USD Million)

Table 16 South America Market by Types, 2017 – 2023, (USD Million)

Table 17 South America Hypersensitivity Pneumonitis Market by Therapy, 2017 – 2023, (USD Million)

Table 18 South America Hypersensitivity Pneumonitis Market by End Users, 2017 – 2023, (USD Million)

Table 19 Europe Market by Types, 2017 – 2023, (USD Million)

Table 20 Europe Hypersensitivity Pneumonitis Market by Therapy, 2017 – 2023, (USD Million)

Table 21 Europe Hypersensitivity Pneumonitis Market by End Users, 2017 – 2023, (USD Million)

Table 22 Western Europe Market by Types, 2017 – 2023, (USD Million)

Table 23 Western Europe Hypersensitivity Pneumonitis Market by Therapy, 2017 – 2023, (USD Million)

Table 24 Western Europe Hypersensitivity Pneumonitis Market by End Users, 2017 – 2023, (USD Million)

Table 25 Eastern Europe Market by Types, 2017 – 2023, (USD Million)

Table 26 Eastern Europe Hypersensitivity Pneumonitis Market by Therapy, 2017 – 2023, (USD Million)

Table 27 Eastern Europe Hypersensitivity Pneumonitis Market by End Users, 2017 – 2023, (USD Million)

Table 28 Asia Pacific Market by Types, 2017 – 2023, (USD Million)

Table 29 Asia Pacific Hypersensitivity Pneumonitis Market by Therapy, 2017 – 2023, (USD Million)

Table 30 Asia Pacific Hypersensitivity Pneumonitis Market by End Users, 2017 – 2023, (USD Million)

Table 31 Middle East & Africa Market by Types, 2017 – 2023, (USD Million)

Table 32 Middle East & Africa Hypersensitivity Pneumonitis Market by Therapy, 2017 – 2023, (USD Million)

Table 33 Middle East & Africa Hypersensitivity Pneumonitis Market by End Users, 2017 – 2023, (USD Million)



LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Hypersensitivity Pneumonitis Market

Figure 3 Segmentation Market Dynamics for Global Hypersensitivity Pneumonitis Market

Figure 4 Global Hypersensitivity Pneumonitis market Share, by Type 2016

Figure 5 Global Hypersensitivity Pneumonitis market Share, by Therapy 2016

Figure 6 Global Hypersensitivity Pneumonitis Market Share, by End Users, 2016

Figure 7 Global Hypersensitivity Pneumonitis Market Share, by Region, 2016

Figure 8 North America Hypersensitivity Pneumonitis Market Share, by Country, 2016

Figure 9 Europe Hypersensitivity Pneumonitis Market Share, by Country, 2016

Figure 10 Asia Pacific Hypersensitivity Pneumonitis Market Share, by Country, 2016

Figure 11 Middle East & Africa Hypersensitivity Pneumonitis Market Share, by Country, 2016

Figure 12 Global Hypersensitivity Pneumonitis Market: Company Share Analysis, 2016 (%)

Figure 13 Novartis AG: Key Financials

Figure 14 Novartis AG: Segmental Revenue

Figure 15 Novartis AG: Geographical Revenue

Figure 16 Abbott: Key Financials

Figure 17 Abbott: Segmental Revenue

Figure 18 Abbott: Geographical Revenue

Figure 19 Eli Lilly: Key Financials

Figure 20 Eli Lilly: Segmental Revenue

Figure 21 Eli Lilly: Geographical Revenue

Figure 22 Sunpharma: Key Financials

Figure 23 Sunpharma: Segmental Revenue

Figure 24 Sunpharma: Geographical Revenue

Figure 25 Sanofi: Key Financials

Figure 26 Sanofi: Segmental Revenue

Figure 27 Sanofi: Geographical Revenue

Figure 28 Novo Nordisk: Key Financials

Figure 29 Novo Nordisk: Segmental Revenue

Figure 30 Novo Nordisk: Geographical Revenue

Figure 31 AstraZeneca: Key Financials

Figure 32 AstraZeneca: Segmental Revenue

Figure 33 AstraZeneca: Geographical Revenue